Skip to content

Effects of HFNC on Moderate and Severe Respiratory Failure Patients

Effects of High Flow Nasal Canula on Moderate and Severe Respiratory Failure Patients

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02687074
Enrollment
246
Registered
2016-02-22
Start date
2016-01-31
Completion date
2017-12-31
Last updated
2016-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Respiratory Failure

Keywords

HFNC, Respiratory Failure, Intubation, Mortality

Brief summary

Respiratory failure is the danger for the patients admitted in ICU, mechanical ventilation could save a lot of patients' life, however, it prolongs patients' ICU stay and hospital stay. High flow nasal cannula (HFNC) has advantages of PEEP effects, reducing dead space, increasing EELV and improving comfort, and it has been used to treat respiratory failure patients. In recent study, HFNC could improve mortality of respiratory failure patients with P/F\<200mmHg in the subgroup. The investigators want to start a randomized controlled study to evaluate the effects of HFNC on the patients with respiratory failure.

Detailed description

just as the brief summary

Interventions

DEVICEHFNC

patients treated with high flow nasal cannula

DEVICENIV

patients treated with noninvasive ventilation

Sponsors

First Affiliated Hospital of Suzhou Medical College
CollaboratorOTHER
Second Affiliated Hospital of Suzhou University
CollaboratorOTHER
Zhangjiagang First People's Hospital
CollaboratorOTHER
The Second Hospital of Nanjing Medical University
CollaboratorOTHER
Wuxi No. 4 People's Hospital
CollaboratorOTHER
Southeast University, China
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

1. Age\>18 years 2. patients met all four of the following criteria: * a respiratory rate of more than 25 breaths per minute, * a ratio of the partial pressure of arterial oxygen (Pao2) to the Fio2 of 300 mm Hg or less while the patient was breathing oxygen at a flow rate of 10 liters per minute or more for at least 15 minutes, * a partial pressure of arterial carbon dioxide (Paco2) not higher than 45 mmHg, and * an absence of clinical history of underlying chronic respiratory failure

Exclusion criteria

1. Paco2 of more than 45 mm Hg 2. exacerbation of asthma or chronic respiratory failure 3. cardiogenic pulmonary edema 4. severe neutropenia 5. hemodynamic instability, use of vasopressors, 6. Glasgow Coma Scale score of 12 points or less (on a scale from 3 to 15, with lower scores indicating reduced levels of consciousness) 7. contraindications to noninvasive ventilation 8. urgent need for endotracheal intubation, a do-not-intubate order, and a decision not to participate.

Design outcomes

Primary

MeasureTime frame
intubation rate on 28 daysup to 28 days

Secondary

MeasureTime frame
Duration of ICU staydate of death from any cause, whichever came first, assessed up to 90 days
Duration of hospital staydate of death from any cause, whichever came first, assessed up to 90 days

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026